The global immuno-oncology clinical trials market is expected to reach 15.1 billion by 2028, according to a new report from Grand View Research Inc.
From 2021 to 2028, the market is expected to grow at a CAGR of 13.6 percent.
Immuno-oncology is a rapidly growing field within the oncology ecosystem, transforming cancer treatment.
In March 2020, the cancer cell therapy pipeline contained 1,483 active compounds, an increase of 472 since March 2019.
Chemical antigen receptor T (CAR-T) cell products were the fastest growing category (up 77 percent from 2019 to 2020).
The number of developing IO drugs rose during the Covid-19 pandemic between 3,876 in 2019 to 4,720 in 2020.